Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Amerikaanse aandelen  /  MINERVA NEUROSCIENCES (NERV)

Ontvang nu dagelijks onze kooptips!

word abonnee

Amerikaanse aandelen« Terug naar discussie overzicht

MINERVA NEUROSCIENCES (NERV)

39 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  8. [verwijderd] 30 mei 2017 13:16
    Minerva Neurosciences Inc (NERV) Moves Higher on Volume Spike for May 29
    Equities Staff ? Follow | Monday, 29 May 2017 17:18 (EST) ? ? ? ?

    Market Summary


    Minerva Neurosciences Inc is a A clinical-stage bio-pharmaceutical company

    Last Price$ 8.30 Last Trade May/26 - 16:00
    Change$ 0.65 Change Percent8.50 %
    Open$ 7.60 Prev Close$ 7.65
    High$ 8.35 low$ 7.60
    52 Week High$ 15.84 52 Week Low$ 6.50
    Market Cap304,650,438 PE Ratio2.86
    Volume232,113 ExchangeNSD

    NERV - Market Data & News

    NERV - Stock Valuation Report
    ? Trade
    Minerva Neurosciences Inc (NERV) traded on unusually high volume on May. 29, as the stock gained 8.5% to close at $8.30. On the day, Minerva Neurosciences Inc saw 232,113 shares trade hands on 1,569 trades. Considering that the stock averages only a daily volume of 145,980 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

    Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

    The stock has traded between $15.84 and $6.50 over the last 52-weeks, its 50-day SMA is now $7.53, and its 200-day SMA $10.80. Minerva Neurosciences Inc has a P/B ratio of 2.86.

    Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases.

    Headquartered in Waltham, MA, Minerva Neurosciences Inc has 11 employees and is currently under the leadership of CEO Remy Luthringer.

    For a complete fundamental analysis analysis of Minerva Neurosciences Inc, check out Equities.com’s Stock Valuation Analysis report for NERV.

    Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit www.equitiespremium.com/ to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

    To get more information on Minerva Neurosciences Inc and to follow
  11. [verwijderd] 1 juni 2017 10:38

    Denk u nu werkelijk dat de topman uit het niets voor 400.000 dollar aandelen koopt?
    Voor Profitmaker die al jaren belegt en ver boven de materie staat was dat een simpel verhaal.
    Heb ook voor aanzienlijk bedragen een tijdje terug aandelen gekocht op een koers onder de 8 dollar (net als de topman) en komende dagen wordt het oogsten. De zomervakantie is met deze eenvoudige trade deal weer binnen :-)
  14. [verwijderd] 1 juni 2017 11:01
    Minerva to gain global strategic control over development of MIN-202 for insomnia

    Janssen cash payments to Minerva of up to $70 million, including $30 million upfront

    All shares in Minerva held by an affiliate of Janssen (approximately 3.9 million shares representing approximately 10% of outstanding shares) to be repurchased at par value

    Minerva Phase 2 development payments totaling $13 million to be waived
  15. [verwijderd] 1 juni 2017 11:03
    Alleen de inkoop van 10 % van het uitstaande aandelenkapitaal zet de koers van het aandeel dus al 10 % hoger vandaag. Los van de bereikte deal die het aandeel ook een forse duw in de rug gaat geven. Ja luitjes het is zo ontzettend simpel voor Profitmaker allemaal. Het kost soms een aantal weken of maanden maar dan komt het geld ook echt met bakken binnen.
  16. [verwijderd] 1 juni 2017 11:07
    Minerva to gain global strategic control over development of MIN-202 for insomnia

    Janssen cash payments to Minerva of up to $70 million, including $30 million upfront

    All shares in Minerva held by an affiliate of Janssen (approximately 3.9 million shares representing approximately 10% of outstanding shares) to be repurchased at par value

    Minerva Phase 2 development payments totaling $13 million to be waived

    WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has entered into a binding term sheet to amend its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922), a selective orexin-2 receptor antagonist, and to repurchase all Minerva shares owned by Johnson & Johnson Innovation - JJDC, Inc. (an affiliate of Janssen). This amendment and the stock repurchase are conditional upon the closing of the pending acquisition of Actelion Ltd. by affiliates of Janssen and approval by the European Commission.

    Under the amended agreement, Minerva will gain global strategic control of the development of MIN-202 to treat insomnia, and Janssen will forego its right to royalties on MIN-202 insomnia sales in Minerva territories. Minerva will retain its current rights to MIN-202 as adjunctive therapy for major depressive disorder (MDD), which include an exclusive license in the European Union, Switzerland, Liechtenstein, Iceland and Norway, with royalties payable by Minerva to Janssen, and royalties on sales payable by Janssen to Minerva elsewhere worldwide.

    Payments to Minerva by Janssen under this new agreement include an upfront payment of $30 million, $20 million at the start of a Phase 3 insomnia trial for MIN-202 and $20 million when 50% of the patients are enrolled in this trial. Janssen will waive the remaining payments due from Minerva for Phase 2 development of MIN-202, which total approximately $13 million. Minerva will assume all financial responsibility for Phase 3 development costs for MIN-202 in insomnia. All Minerva stock currently owned by Johnson & Johnson Innovation - JJDC, Inc. totaling approximately 3.9 million shares and representing approximately 10% of total Minerva shares outstanding will be repurchased by Minerva at par value of $.0001 per share or approximately $389 in total.

    “We view the new agreement with Janssen as a structure that will ensure a more focused and efficient clinical development of MIN-202 in insomnia by Minerva,” said Dr. Remy Luthringer, president and chief executive officer of Minerva. “We look forward to continuing our collaboration with Janssen while accelerating the clinical advancement of our portfolio. In addition, the infusion of financial resources under this agreement significantly extends Minerva’s financial runway.”

    Minerva expects that these combined financial resources will support the development of MIN-101, its lead product candidate to treat negative symptoms in schizophrenia, and the development of MIN-202 in insomnia and MDD to the end of 2019. Within that time frame, Minerva expects to generate data readouts from its planned Phase 3 trial with MIN-101 and three Phase 2b trials with MIN-202 in both indications. Additional clinical activities planned during that period include a Phase 2 trial with MIN-117 and a Phase 1 trial with MIN-301.

    About MIN-202 (JNJ 42827922)

    MIN-202 is a selective orexin 2 receptor antagonist under development for the treatment of insomnia and as adjunctive therapy for MDD. In the brain, the orexin system is involved in the control of several key functions, including metabolism and wakefulness. MIN-202 seeks to inhibit the activity of the neurons that promote wakefulness by selectively blocking the orexin 2 receptor. Rather than making an individual sleepier, blocking the orexin 2 receptor reduces the level of the neurotransmitters that signal the brain to maintain vigilance and wakefulness.

    About Minerva Neurosciences

    Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
  17. [verwijderd] 1 juni 2017 15:46

    www.google.com/finance?q=NASDAQ%3ANER...

    Profitmaker staat al jaren boven de materie en dat is uiteraard lekker verdienen.

    Daarna volgen vaak de kuddedieren. Het is de kunst die steeds voor te zijn en het lekkerste stukje vlees nog voor de grote koersstijging in te slaan. En dat lukt hem steeds aardig!
  20. [verwijderd] 2 juni 2017 18:37

    Zoals PM gisteren messcherp aangaf kwam de koerswinst precies uit in de door PM voorspelde bansbreedte van 15-25%. Hoe scherp kan een mens het zien !
    Voor juni verwacht PM een verdere stijging naar 12 dollar om in de loop van het jaar door te stijgen naar 15 dolar. Een 50% koerswinst in de resterende 7 maanden verwacht PM zeker.
    Den koersstijging van gisteren is nog maar het begin. De trein is net vertrokken!
39 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0655 +0,11%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.714,20 -0,13%
Gold spot 2.392,50 0,00%
NY-Nasdaq Composite 15.282,01 -2,05%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!